Navitas Life Sciences, a TAKE Solutions Enterprise announced the acquisition of US based niche full service CRO and health research company, KAI Research Inc.
KAI Research brings offerings in three key areas – Clinical Trial Management, Clinical Research Consultation, and Data Management & Standardization. Through this acquisition, Navitas Life Sciences expands Phase II and Phase III capabilities in North America adding to its current capabilities in Europe and APAC. The company has differentiated offerings in the areas of patient registries and e-clinical solutions as well as long-standing relationships with clinical sites and trusted network of service providers across the United States and Africa.
Srinivasan H R, Managing Director, Navitas Life Sciences said, “We are on track in terms of our acquisitions, KAI Research will further strengthen our capabilities in clinical services and expand our therapeutic expertise. Through this acquisition, we also gain a unique standpoint in serving Federal agencies like FDA, NIH, CDC, Department of Defense etc. Together, we intend to create a world class enterprise making meaningful strides in our ability to deliver improved trial outcomes to the bio pharma landscape. The addition of KAI’s capabilities translates to global trial capabilities across North America, Europe and APAC markets. Combining these operational and TA capabilities with our proprietary AI driven OneClinical platform allows us to be a great partner to small and mid-tier customers as well as to large pharma.”
Kathy Dimeo, President, KAI Research Inc said, “We are happy to share that we have been acquired by Navitas Life Sciences. The complementary synergies between our companies will increase service offerings and capacity to serve our current and prospective clients and improve the quality of our service delivery, while opening our services to the global community.”
Benefits of the acquisition:
Clinical delivery capability synergies
- Conduct and manage clinical trials in USA for global customers by leveraging KAI’s strong delivery capabilities
- Augment domain expertise and improve quality of delivery with KAI’s domain strength and consulting capabilities
- Enhance data management and standardization efforts required by FDA regulated environment
Augmented client base
- Support larger and more complex Clinical Deals with addition of sites and local clinical trial management capabilities in USA
- Conduct long-term and large-ticket federal studies through KAI’s strong client base of federal agencies
- Expand market reach to attract North American SMEs with KAI’s expertise in the growing biotech and medical device market
